Analyst Alan Carr works at NEEDHAM and is focused on the Healthcare sector with 139 price targets and ratings documented since 2012 spanning on 15 stocks. Analyst's average stock valuation to be materialised ratio is 59.16% with an average time for price targets to be met of 172.87 days.
Most recent stock forecast was given on CRSP, CRISPR Therapeutics AG at 13-May-2022.
Alan Carr best performing recommendations are on ALNY (ALNYLAM PHARMACEUTICALS, INC).
The best stock recommendation documented was for ALNY (ALNYLAM PHARMACEUTICALS, INC) at 9/19/2017. The price target of $85 was fulfilled within 1 day with a profit of $9.96 (13.27%) receiving and performance score of 132.73.
Average potential price target upside
Currently, out of the existing stock ratings of Alan Carr - 7395 which are a Buy (92.52%), 598 which are a Hold (7.48%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
70
$26.57 (61.18%)
70
26 days ago
3/5 (60%)
$22.07 (33.09%)
116
Buy
102.06
$58.63 (135.00%)
122
1 months 2 days ago
4/10 (40%)
$44.21 (64.56%)
30
Buy
123
$79.57 (183.21%)
154
1 months 3 days ago
2/9 (22.22%)
$65.97 (99.34%)
22
Hold
65
$21.57 (49.67%)
78
1 months 3 days ago
2/5 (40%)
$14.36 (26.69%)
41
Hold
63
$19.57 (45.06%)
83
4 months 2 days ago
6/12 (50%)
$-21.25 (-23.42%)
184
